Etsu Tsuzuki Fuse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Etsu Tsuzuki Fuse has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Marumo
Department of Hematology Nippon Medical School Tokyo Japan
1 shared publication Haruka Okabe
Division of Internal Medicine, Fussa Hospital, Tokyo, JPN
1 shared publicationHisae Sugihara
Division of Clinical Laboratory, Fussa Hospital, Tokyo, JPN
1 shared publicationHitoshi Niino
1 shared publication- Junichi Aoyama
Division of Internal Medicine, Fussa Hospital, Tokyo, JPN
1 shared publication Kensuke Arai
Division of Internal Medicine, Fussa Hospital, Tokyo, JPN
1 shared publication
Latest Publications
- Open Access
- 6 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31210
Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan
Background: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, causing widespread mortality. Many patients with COVID-19 have been treated in homes, hotels, and medium-sized hospitals where doctors were responsible for assessing the need for critical care hospitalization. This study aimed to establish a severity prediction score for critical care triage. Method: We analyzed the data of 368 patients with mild-to-moderate COVID-19 who had been admitted to Fussa Hospital, Japan, from April 2020 to February 2022. We defined a high-oxygen group as requiring ≥4 l/min of oxygen. Multivariable logistic regression was used to construct a risk prediction score, and the best model was selected using a stepwise selection method. Results: Multivariable analysis showed that older age (≥70 years), elevated creatine kinase (≥127 U/L), C-reactive protein (≥2.19 mg/dL), and ferritin (≥632.7 ng/mL) levels were independent risk factors associated with the high-oxygen group. Each risk factor was assigned a score ranging from 0 to 4, and we referred to the final overall score as the Fussa score. Patients were classified into two groups, namely, high-risk (total risk factors, ≥2) and low-risk (total risk score, < 0.0001). Conclusions: The Fussa score might help to identify patients with COVID-19 who require critical care hospitalization.
- 6 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31210
Open AccessClinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan
Background: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, causing widespread mortality. Many patients with COVID-19 have been treated in homes, hotels, and medium-sized hospitals where doctors were responsible for assessing the need for critical care hospitalization. This study aimed to establish a severity prediction score for critical care triage. Method: We analyzed the data of 368 patients with mild-to-moderate COVID-19 who had been admitted to Fussa Hospital, Japan, from April 2020 to February 2022. We defined a high-oxygen group as requiring ≥4 l/min of oxygen. Multivariable logistic regression was used to construct a risk prediction score, and the best model was selected using a stepwise selection method. Results: Multivariable analysis showed that older age (≥70 years), elevated creatine kinase (≥127 U/L), C-reactive protein (≥2.19 mg/dL), and ferritin (≥632.7 ng/mL) levels were independent risk factors associated with the high-oxygen group. Each risk factor was assigned a score ranging from 0 to 4, and we referred to the final overall score as the Fussa score. Patients were classified into two groups, namely, high-risk (total risk factors, ≥2) and low-risk (total risk score, < 0.0001). Conclusions: The Fussa score might help to identify patients with COVID-19 who require critical care hospitalization.
- 31 March 2008
- Published by Elsevier in Lung Cancer
- Vol. 59 (3) , 403-406
Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: A case report
- 31 March 2008
- Published by Elsevier in Lung Cancer
- Vol. 59 (3) , 403-406
Response of a thymic mucoepidermoid carcinoma to combination chemotherapy with cisplatin and irinotecan: A case report